213 related articles for article (PubMed ID: 34506008)
1. Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies.
Illiano M; Colinard M; Taque S; Mallon B; Larue C; Laithier V; Vérité-Goulard C; Sudour-Bonnange H; Faure-Conter C; Coze C; Aerts I; De Maricourt CD; Paillard C; Branchereau S; Brugières L; Fresneau B
Hepatol Int; 2022 Feb; 16(1):125-134. PubMed ID: 34506008
[TBL] [Abstract][Full Text] [Related]
2. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study.
Zsiros J; Brugieres L; Brock P; Roebuck D; Maibach R; Zimmermann A; Childs M; Pariente D; Laithier V; Otte JB; Branchereau S; Aronson D; Rangaswami A; Ronghe M; Casanova M; Sullivan M; Morland B; Czauderna P; Perilongo G;
Lancet Oncol; 2013 Aug; 14(9):834-42. PubMed ID: 23831416
[TBL] [Abstract][Full Text] [Related]
4. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin.
Sivaprakasam P; Gupta AA; Greenberg ML; Capra M; Nathan PC
J Pediatr Hematol Oncol; 2011 Aug; 33(6):e226-30. PubMed ID: 21792028
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2.
Perilongo G; Shafford E; Maibach R; Aronson D; Brugières L; Brock P; Childs M; Czauderna P; MacKinlay G; Otte JB; Pritchard J; Rondelli R; Scopinaro M; Staalman C; Plaschkes J;
Eur J Cancer; 2004 Feb; 40(3):411-21. PubMed ID: 14746860
[TBL] [Abstract][Full Text] [Related]
6. Tumor rupture in hepatoblastoma: A high risk factor?
Pondrom M; Pariente D; Mallon B; Taque S; Branchereau S; Chardot C; Laithier V; Tabone MD; Lejeune J; Faure-Conter C; Saumet L; Vérité C; Aerts I; Brugières L; Fresneau B
Pediatr Blood Cancer; 2020 Sep; 67(9):e28549. PubMed ID: 32618436
[TBL] [Abstract][Full Text] [Related]
7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
8. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR; Maibach R; Childs M; Rajput K; Roebuck D; Sullivan MJ; Laithier V; Ronghe M; Dall'Igna P; Hiyama E; Brichard B; Skeen J; Mateos ME; Capra M; Rangaswami AA; Ansari M; Rechnitzer C; Veal GJ; Covezzoli A; Brugières L; Perilongo G; Czauderna P; Morland B; Neuwelt EA
N Engl J Med; 2018 Jun; 378(25):2376-2385. PubMed ID: 29924955
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
10. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.
Zsíros J; Maibach R; Shafford E; Brugieres L; Brock P; Czauderna P; Roebuck D; Childs M; Zimmermann A; Laithier V; Otte JB; de Camargo B; MacKinlay G; Scopinaro M; Aronson D; Plaschkes J; Perilongo G
J Clin Oncol; 2010 May; 28(15):2584-90. PubMed ID: 20406943
[TBL] [Abstract][Full Text] [Related]
12. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
13. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial.
Katzenstein HM; Langham MR; Malogolowkin MH; Krailo MD; Towbin AJ; McCarville MB; Finegold MJ; Ranganathan S; Dunn S; McGahren ED; Tiao GM; O'Neill AF; Qayed M; Furman WL; Xia C; Rodriguez-Galindo C; Meyers RL
Lancet Oncol; 2019 May; 20(5):719-727. PubMed ID: 30975630
[TBL] [Abstract][Full Text] [Related]
14. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT.
Hishiki T; Matsunaga T; Sasaki F; Yano M; Ida K; Horie H; Kondo S; Watanabe K; Oue T; Tajiri T; Kamimatsuse A; Ohnuma N; Hiyama E
Pediatr Surg Int; 2011 Jan; 27(1):1-8. PubMed ID: 20922397
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma.
Blouin P; Brugières L; Tabone MD; Leverger G; Rubie H; Branchereau S; De Kraker J
Pediatr Blood Cancer; 2004 Feb; 42(2):149-54. PubMed ID: 14752879
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of dose-dense cisplatin-based chemotherapy in Japanese children with high-risk hepatoblastoma: Analysis of the JPLT3-H pilot study.
Watanabe K; Mori M; Hishiki T; Yokoi A; Ida K; Yano M; Fujimura J; Nogami Y; Iehara T; Hoshino K; Inoue T; Tanaka Y; Miyazaki O; Takimoto T; Yoshimura K; Hiyama E
Pediatr Blood Cancer; 2022 Feb; 69(2):e29389. PubMed ID: 34606680
[TBL] [Abstract][Full Text] [Related]
17. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology.
von Schweinitz D; Byrd DJ; Hecker H; Weinel P; Bode U; Bürger D; Erttmann R; Harms D; Mildenberger H
Eur J Cancer; 1997 Jul; 33(8):1243-9. PubMed ID: 9301450
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes and prognostic factors in children with hepatoblastoma using a risk-stratified approach.
Srinivasan S; Prasad M; Parambil BC; Shrimal A; Gollamudi VRM; Subramani V; Ramadwar M; Khanna N; Baheti AD; Gala K; Patil V; Laskar S; Qureshi S; Chinnaswamy G
Pediatr Blood Cancer; 2023 Jul; 70(7):e30302. PubMed ID: 37046413
[TBL] [Abstract][Full Text] [Related]
19. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group.
Schnater JM; Aronson DC; Plaschkes J; Perilongo G; Brown J; Otte JB; Brugieres L; Czauderna P; MacKinlay G; Vos A
Cancer; 2002 Feb; 94(4):1111-20. PubMed ID: 11920482
[TBL] [Abstract][Full Text] [Related]
20. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer.
Knijnenburg SL; Mulder RL; Schouten-Van Meeteren AY; Bökenkamp A; Blufpand H; van Dulmen-den Broeder E; Veening MA; Kremer LC; Jaspers MW
Cochrane Database Syst Rev; 2013 Oct; (10):CD008944. PubMed ID: 24101439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
